Completed PHASE2 INTERVENTIONAL 3-arm NCT03799510

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial

Sponsor: Access to Advanced Health Institute (AAHI)

Conditions Schistosomiasis

Interventions GLA-SE solution Sm14

Updated 8 times since 2019 Last updated: Dec 5, 2019 Started: Dec 13, 2018 Primary completion: Jul 1, 2019 Completion: Aug 7, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Schistosomiasis, this trial is completed. The trial is conducted by Access to Advanced Health Institute (AAHI) and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Mar 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE2
Feb 2019 — Mar 2019 [monthly]

Active Not Recruiting PHASE2

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Access to Advanced Health Institute (AAHI)
Biomedical Research Center EPLS
Orygen Biotecnologia SA
Oswaldo Cruz Foundation

Data source: Oswaldo Cruz Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint-Louis, Senegal